Valid: May 15, 2013 – May 15, 2014
This activity was developed for:
- Primary care providers
- Health plan medical directors
- Health plan pharmacy directors and clinical pharmacists
- Case managers
- Nurse practitioners and physician assistants
The purpose of this activity is to enhance competence of physicians, nurses, and pharmacists concerning the treatment of multiple sclerosis.
Physician Credit Designation
The Medical Learning Institute Inc designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical Learning Institute Inc and the Center of Excellence Media, LLC. The Medical Learning Institute Inc is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Registered Nurse Designation
Medical Learning Institute Inc
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour.
Registered Pharmacy Designation
The Medical Learning Institute Inc is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-12-031-H01-P.
Upon completion of this activity, the participant will be able to:
- Explain the family, societal, and economic impact of MS-associated decline in physical and cognitive function
- Discuss recent advances in the treatment and symptom management of MS
- Review the issues complicating early diagnosis, treatment, and medication adherence.
- Formulate effective, patient-tailored management strategies for improving outcomes and quality of life for patients with MS
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute Inc, the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CPE/CE activity for any mount during the past 12 months.
Planners’ and Managers’ Disclosures
William J. Wong, MD, MLI Reviewer, has nothing to disclose.
Lorrie McSherry, RN, BSN, OCN, MLI Reviewer, has disclosed that she is on the advisory board for Onyx.
Teresa Haile, RPh, MBA, MLI Reviewer, has nothing to disclose.
Mary Mihalovic, Medical Writer, has nothing to disclose. She does not intend to discuss any non-FDA-approved or investigational use of any product or device.
Samuel F. Hunter, MD, PhD, is a speaker, consultant, and does research for Biogen Idec and Novartis Pharmaceuticals. He is a speaker and consultant to Accorda and Bayer Healthcare. He is a consultant and does research for Roche. He is also a speaker and does research for Teva Neurosciences. He does intend to discuss either non-FDA-approved or investigational use for the following products/ devices: progressive and refractory MS situations for which they are not labeled.
Daniel Kantor, MD, discloses that he is a speaker, consultant, and does research for Acorda, Allergan, Avanir, Biogen, Novartis, Questcor, and Teva. He does not intend to discuss any non-FDA-approved or investigational use of any product or device.
The information provided at this CME/CPE/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent-discussed in this program should be inferred.
Instructions for Credit
For pharmacists, Medical Learning Institute Inc will report your participation in this educational activity to the NABP ONLY if you provide your NABP e-Profile number and date of birth. For more information regarding this process or to get your NABP e-Profile number: go to www.mycpemonitor.net.
Samuel F. Hunter, MD, PhD
President, Advanced Neurosciences Institute
Director, NeuroNexus Center for Neurology Education and Research
Daniel Kantor, MD
Ponte Vedra, Florida
Florida Society of Neurology
This activity is jointly sponsored by Medical Learning Institute Inc and Center of Excellence Media, LLC.
Commercial Support Acknowledgment
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Estimated time to complete activity: 1 hour
Date of initial release: May 15, 2013
Valid for CME/CPE/CE credit through: May 15, 2014